Table 3.
Characteristics of acquired demyelinating disorders of the central nervous system in children
| Diagnosis | Age at test (years; mean ± SD) | Serum α-synuclein (ng/ml) (mean ± SD) | Patient ID | Number of tests | Number of relapses | Medications | Outcome |
|---|---|---|---|---|---|---|---|
| Acute disseminated encephalomyelitis | 7.9 ± 1.8 | 9.5 ± 1.9 | A | 1 | None | IVIG, PD | Completely recovered |
| B | 1 | None | IVIG, PD | Completely recovered | |||
| Multiple sclerosis | 13.9 ± 0.1 | 11.0 ± 7.4 | C | 3 times | 3 times | IVIG+PD+ interferon-β | Relapsing–remitting type |
| Neuromyelitis optica spectrum disorder | 8.7 ± 3.6 | 13.7 ± 4.8 | D | 1 | 2 times | IVIG+PD+ AZP + plasmapheresis | Expired |
| E | 2 times | 3 times | IVIG+PD+ AZP | Rapid disease progression; bedridden with home ventilator | |||
| F | 5 times | 4 times | IVIG+PD+ AZP | Slow disease progression, but can walk independently | |||
| Transverse myelitis | 3.8 ± 1.8 | 10.8 ± 7.9 | G | 1 | None | IVIG+PD | Rapidly and completely recovered |
| H | 1 | None | IVIG+PD | Rapidly and completely recovered | |||
| I | 3 times | None | IVIG+PD | Unresponsive to treatment for the first two months, but slowly recovered |
SD; standard deviation, ID; identification, IVIG, intravenous immunoglobulin; PD; prednisolone, AZP; azathioprine